Thomas E Spires
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Thomas E Spires has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Cheryl A Rizzo
Oncology Drug Discovery, Pharmaceutical Research Institute, Bristol-Myers Squibb Company, Princeton, NJ, USA
1 shared publication - J Suso Platero
Clinical Discovery Technologies, Pharmaceutical Research Institute, Bristol-Myers Squibb Company, Princeton, NJ, USA
1 shared publication - Liang Schweizer
Bristol Myers Squibb Company Princeton New Jersey
1 shared publication - Marco M Gottardis
Oncology Drug Discovery, Pharmaceutical Research Institute, Bristol-Myers Squibb Company, Princeton, NJ, USA
1 shared publication - Qiuyan Wu
Clinical Discovery Technologies, Pharmaceutical Research Institute, Bristol-Myers Squibb Company, Princeton, NJ, USA
1 shared publication - Ricardo M Attar
Oncology Drug Discovery, Pharmaceutical Research Institute, Bristol-Myers Squibb Company, Princeton, NJ, USA
1 shared publication
Latest Publications
- Open Access
- 24 January 2008
- Published by Springer Nature in BMC Cell Biology
- Vol. 9 (1) , 4
The androgen receptor can signal through Wnt/β-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens
A crucial event in Prostate Cancer progression is the conversion from a hormone-sensitive to a hormone-refractory disease state. Correlating with this transition, androgen receptor (AR) amplification and mutations are often observed in patients failing hormonal ablation therapies. β-Catenin, an essential component of the canonical Wnt signaling pathway, was shown to be a coactivator of the AR signaling in the presence of androgens. However, it is not yet clear what effect the increased levels of the AR could have on the Wnt signaling pathway in these hormone-refractory prostate cells.
- 24 January 2008
- Published by Springer Nature in BMC Cell Biology
- Vol. 9 (1) , 4
Open AccessThe androgen receptor can signal through Wnt/β-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens
A crucial event in Prostate Cancer progression is the conversion from a hormone-sensitive to a hormone-refractory disease state. Correlating with this transition, androgen receptor (AR) amplification and mutations are often observed in patients failing hormonal ablation therapies. β-Catenin, an essential component of the canonical Wnt signaling pathway, was shown to be a coactivator of the AR signaling in the presence of androgens. However, it is not yet clear what effect the increased levels of the AR could have on the Wnt signaling pathway in these hormone-refractory prostate cells.